HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

L-Folinic acid

HCID 135398559
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
68538-85-2
Standard SMILES
Nc1nc2c(c(=O)[nH]1)N(C=O)[C@@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2
InChIKey
VVIAGPKUTFNRDU-STQMWFEESA-N
Molecular formula
C20H23N7O7
Average molar mass
473.4 g/mol
Monoisotopic mass
473.1658961

Overview

(6S)-5-formyltetrahydrofolic acid is the pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid. It has a role as a metabolite and an antineoplastic agent. It is a conjugate acid of a (6S)-5-formyltetrahydrofolate(2-).

Names & identifiers

Preferred name
L-Folinic acid
IUPAC
(2S)-2-[[4-[[(6S)-2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
English name
(2S)-2-[[4-[[(6S)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6- yl]methylamino]benzoyl]amino]pentanedioic acid
Molecular formula
C20H23N7O7
Molecular weight
473.44

Names & synonyms

LevoleucovorinLevofolinic acidL-Folinic acidLevofolene68538-85-2(S)-Leucovorin(6S)-Leucovorin(6S)-Folinic acid(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acidKHAPZORYLFP-754990S25980Y
Show more names
(6S)-5-Formyltetrahydrofolic acidFolinic Acid EP Impurity HImpurity H of Calcium LevofolinateFolinic Acid Impurity H (Levofolinic Acid)N-[4-[[(2-Amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic AcidL-Glutamic acid, N-[4-[[[(6S)-2-amino-5-formyl-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl]methyl]amino]benzoyl]-(-)-N-[4-[[[(6S)-2-Amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxopteridin-6β-yl]methyl]amino]benzoyl]-L-glutamic acid
DTXSID4023204CHEBI:63606L-Glutamic acid, N-(4-((((6S)-2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-(2S)-2-[[4-[[(6S)-2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acidlevofolinatelevo leucovorinlevo-leucovorinS leucovorin

Properties

Computed structural propertiesFilling in

XLogP
-1.2
Topological polar surface area
216 Ų
Hydrogen bond donors
7
Hydrogen bond acceptors
10
Rotatable bonds
9
Heavy atoms
34
Formal charge
0
Complexity
911

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 3 items

Breast Feeding; Lactation; Milk, Human; Antidotes; Vitamin B Complex; Vitamins

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physical DescriptionSolid

Physicochemical properties

Density
1.68 · 1.68±0.1 g/cm3(Predicted)
pka
3.51 · 3.51±0.10(Predicted)
FDA UNII
990 S25980Y · 990S25980Y

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Health EffectsShould not be administered intrathecally as this may produce severe adverse effects or even death when administered. [Wikipedia]. Allergic sensitization (<1%), including anaphylactoid reactions
Exposure RoutesFollowing oral administration, leucovorin is rapidly absorbed. The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
Toxicity Summary · 1 item

As leucovorin is a derivative of folic acid, it can be used to increase levels of folic acid under conditions favoring folic acid inhibition (following treatment of folic acid antagonists such as methotrexate). Leucovorin enhances the activity of fluorouracil by stabilizing the bond of the active metabolite (5-FdUMP) to the enzyme thymidylate synthetase.

Signs and SymptomsExcessive amounts of leucovorin may nullify the chemotherapeutic effect of folic acid antagonists.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Levoleucovorin

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: >8000 mg/kg (oral, rats).

Chemistry & industry

Pharmacology

Protein BindingDoes not bind human serum albumin.
Pharmacodynamics · 1 item

Levoleucovorin is actively and passively transported across cell membranes. In vivo, levoleucovorin is converted to 5-methyltetrahydrofolic acid (5-methyl-THF), the primary circulating form of active reduced folate. Levoleucovorin and 5-methyl-THF are polyglutamated intracellularly by the enzyme folylpolyglutamate synthetase. Folylpolyglutamates are active and participate in biochemical pathways that require reduced folate.

Mechanism of Action · 1 item

Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted when high-dose methotrexate is used for cancer therapy. As methotrexate functions as a DHFR inhibitor to prevent DNA synthesis in rapidly dividing cells, it also prevents the formation of DHF and THF. This results in a deficiency of coenzymes and a resultant buildup of toxic substances that are responsible for numerous adverse side effects of methotrexate therapy. As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects.

Biological Half-LifeThe mean terminal half-life for total-THF and (6S)-5-methyl-5,6,7,8-tetrahydrofolate was 5.1 and 6.8 hours, respectively.
Metabolism/Metabolites · 2 items

Extensively converted to tetrahydrofolic derivatives.

Hepatic and intestinal mucosal, the main metabolite being the active 5-methyltetrahydrofolate. Leucovorin is readily converted to another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of fluorodeoxyridylic acid to thymidylate synthase and thereby enhances the inhibition of this enzyme. Half Life: 6.2 hours

Related reactions

1 records
New reaction record
HRID 1614708 reaction equation
HRID 1614708As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
68538-85-2
PubChem CID
135398559
DTXSID
DTXSID4023204
ChEMBL
CHEMBL1908841
ChEBI
CHEBI:63606
UNII
990S25980Y
Nikkaji
J185.512C
FDA Pharmacological Classification · 6 items

990S25980Y

LEVOLEUCOVORIN

Established Pharmacologic Class [EPC] - Folate Analog

Chemical Structure [CS] - Folic Acid

Levoleucovorin is a Folate Analog.

LEVOLEUCOVORIN

MeSH Pharmacological ClassificationAgents counteracting or neutralizing the action of POISONS.
Absorption, Distribution and Excretion · 4 items

After rapid intravenous administration, serum total tetrahydrofolate (total-THF) concentrations reached a mean peak of 1722 ng/mL. Serum (6S)-5-methyl-5,6,7,8-tetrahydrofolate concentrations reached a mean peak of 275 ng/mL and the mean time to peak was 0.9 hours.

Urinary.

Data can't be found.

Data can't be found.

Tissue LocationsBladder
Cellular LocationsExtracellular
Metabolite PathwaysFolate malabsorption, hereditary

Uses & manufacturing

Uses · 1 item

For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Used in cancer chemotherapy involving the drug methotrexate.

Applications · 1 item

UsesLevoleucovorin (Levofolinic acid) is the pharmacologically active levoisomer of racemic leucovorin. Levoleucovorin can be used as a rescue agent after high-dose Methotrexate (HY-14519) therapy, and in combination with fluorouracil for the research of advanced metastatic colorectal cancer[1].

Additional notes

DefinitionChEBI: The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.